15.07.2015 • News • Dede Willams • Mergers & Acquisitions (M&A) • Bundeskartellamt

German Antitrust Authority Allows BASF-Siegfried Deal

Germany’s antitrust authority Bundeskartellamt has approved BASF’s plans to sell its custom synthesis business, part of the Nutrition & Health division, and parts of its current active pharmaceutical ingredients (APIs) business to Zofingen, Switzerland-based Siegfried Holding.

Following the divestment, which has an enterprise value of €270 million, BASF intends to focus on products for which it has a leading market position.

Siegfried will acquire APIs such as ephedrine, pseudoephedrine and caffeine, with annual sales of around €270 million, while BASF will retain its excipient portfolio and selected APIs, such as ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG).

The Swiss company said it expects the transaction be finalized at the beginning of the fourth quarter.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature